The Brightline Initiative Announces Research Collaborations with Technical University of Denmark, University of Tokyo Global Teamwork Lab and the Massachusetts Institute of Technology Consortium for Engineering Program Excellence
The Brightline Initiative today announced research collaborations with Technical University of Denmark (DTU), University of Tokyo Global Teamwork Lab (GTL) and the Massachusetts Institute of Technology (MIT) Consortium for Engineering Program Excellence (CEPE). The initiative will focus on cutting-edge research and solutions for strategy implementation.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180130005754/en/
Launched in early 2017 by Project Management Institute (PMI), The Boston Consulting Group (BCG) and the Agile Alliance, the Brightline™ Initiative is a non-commercial coalition of leading global organizations dedicated to helping executives bridge the expensive and unproductive gap between strategy design and delivery. The Brightline Initiative focuses its work on three key areas: Thought and Practice Leadership, Networking and Capability Building.
“At DTU we are excited to join the Brightline coalition. It is DTU’s mission to create tangible societal benefits. That is why, when we create new scientific insights and technologies we also focus on implementing them in the day-to-day operations of organizations and on a broader system level. Therefore, we believe our goals and those of Brightline align very well,” said Søren Salomo, Head of Department, DTU Management Engineering.
“We are looking forward to making our contribution to improving strategy implementation, particularly by our research on better managing the associated risks and uncertainties in technology-driven organizations,” said Josef Oehmen, Associate Professor at DTU.
“The collaboration with the Brightline Initiative presents a unique venue to explore the intersection of strategy development and planning with the pragmatic aspects of operations, organizational learning, and change. We’re particularly excited for the opportunity to develop sophisticated new research methods to uncover original insights into how decisions are made and translated into action and results,” said Eric Rebentisch, Research Associate at MIT.
Strategy is a living thing that adapts.  In a world with constant disruptions, an organization needs to engage with its ecosystem in designing and implementing its strategy. Collaboration and communication, knowledge and capabilities form the cornerstone of successful strategy executive.
Dr. Kazuo Hiekata, Associate Professor at The University of Tokyo, noted, "The GTL team is evolving methods and tools for system of systems to facilitate communication across boundaries. Our joint activity with Brightline Initiative will deliver both excellent research outcomes and significant impact to the society, by connecting executives and experienced employees in novel ways of communication." Dr. Kenji Tanaka, Project Associate Professor, added, ”Established industries such as the energy sector are required to change significantly from existing ways with the emergence of new technologies and services. The strategy and execution for established business should differ greatly."
Dai Ike, GTL Research Coordinator and GPD Japan CEO, further commented, "Japanese companies are seeking an advanced methodology and cross-boundary teams to execute the complex and diverse projects which directly link to the corporate strategy. However, at the same time, those companies hesitate to challenge the new way of business until other companies succeed. GTL success stories are exactly what companies are looking for."
Brightline Executive Director Ricardo Vargas highlights, “The collaborations with DTU, GTL, and MIT Research entities reinforce Brightline’s mission in bridging the gap between strategy design and delivery through cutting-edge research. Organizations and leaders will benefit from best practices in their endeavor for strategy delivery in this era of disruptive innovation. DTU, GTL and the MIT groups bring unique perspectives from their research fields. Their experience and knowledge on strategy will add enormous value in our collective quest to succeed in strategy initiative management.”
About Brightline Initiative
The Brightline™ Initiative is a non-commercial coalition of leading global organizations dedicated to helping executives bridge the expensive and unproductive gap between strategy design and delivery. Brightline provides organizations with three key benefits that will improve their ability to deliver on strategic intent: Thought and Practice Leadership, Networking, and Capability Building. Learn more at www.brightline.org.
About Technical University of Denmark
The Technical University of Denmark is at the academic and
multidisciplinary forefront of the technical and the natural
sciences—with new initiatives in a number of demanding engineering
disciplines, including sustainable energy technology and life science.
About University of Tokyo Global Teamwork Lab (GTL)
The University of Tokyo Global Teamwork Lab (GTL) is an
industry-university partnership for research, workshops, and education
on teamwork across boundaries. The GLT research focuses on the
underlying mechanisms and dynamics of performance under complexity.
1] Economist Intelligence Unit (EIU), “Closing the Gap: Designing and Delivering a Strategy that Works”, 2017.
The Brightline Initiative
Organizations Relationship Manager
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45 | Tiedote
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10 | Tiedote
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme